Related Experiment Videos
Failure of orally administered RA233 to influence B16 melanoma growth or metastasis
Abstract:
Possible prophylactic antitumor and/or antimetastatic effects of long-term oral administration of a potent inhibitor of platelet aggregation, the pyrimido-pyrimidine derivative RA233, were assessed using four phenotypically distinct clones of the mouse B16 melanoma. The clones tested included: a poorly tumorigenic, very slowly growing and poorly metastatic population (G3.15); a moderately tumorigenic and slowly growing population that frequently metastasizes to the lungs (G3.5); a highly tumorigenic, moderately growing and highly metastatic population (G3.12); and a highly tumorigenic and rapidly growing population that is generally nonmetastatic but can be slightly metastatic when tumors are initiated by very small numbers of cells (G3.26). Addition of 0.5 mg/ml RA233 to the drinking water continuously from the time of subcutaneous injection of cultured tumor cells until death from tumor growth, which resulted in a daily uptake of 80-100 mg/kg of drug per mouse, failed to significantly influence the tumorigenicities, tumor growth rates, metastatic incidences, or metastatic burdens of any of these clones. RA233 at doses equivalent to those delivered daily to experimental animals strongly inhibited ADP-induced aggregation of homologous C57BL/6 mouse platelets and exhibited selective anti-proliferative effects on cultured cells. Although RA233 prolonged bleeding times, pharmacokinetic analysis indicated that clearance of RA233 from mice was so rapid that achievement of sustained circulating levels sufficient to influence tumor cells or platelet-tumor cell interactions by oral administration was unlikely.
Insights
Long-term oral administration of RA233, a platelet aggregation inhibitor, did not prevent tumor growth or metastasis in mouse melanoma models. Rapid drug clearance limited its potential prophylactic effects.
Area of Science:
- Oncology
- Pharmacology
- Cancer Metastasis
Background:
- Platelet aggregation inhibitors are being investigated for potential antitumor and antimetastatic effects.
- RA233 is a potent pyrimido-pyrimidine derivative that inhibits platelet aggregation.
Purpose of the Study:
- To evaluate the prophylactic antitumor and antimetastatic effects of long-term oral administration of RA233.
- To assess RA233's impact on tumorigenicity, tumor growth, and metastasis in distinct mouse B16 melanoma clones.
Main Methods:
- Four phenotypically distinct mouse B16 melanoma clones were used.
- Mice received RA233 in drinking water from tumor cell injection until death.
- Drug uptake, tumorigenicity, tumor growth, metastasis, and platelet aggregation were monitored.
Main Results:
- RA233 administration failed to significantly influence tumorigenicity, tumor growth rates, or metastatic burden across all melanoma clones.
- RA233 effectively inhibited ADP-induced platelet aggregation and showed anti-proliferative effects on cultured cells in vitro.
- Pharmacokinetic analysis revealed rapid clearance of RA233 in mice, suggesting insufficient sustained drug levels.
Conclusions:
- Long-term oral administration of RA233 did not demonstrate prophylactic antitumor or antimetastatic effects in this B16 melanoma mouse model.
- The rapid clearance of RA233 limits its therapeutic potential for sustained systemic effects via oral administration.
- Further research may be needed to explore alternative delivery methods or different drug candidates for cancer treatment.